Compare IPHA & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | IMMR |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | France | United States |
| Employees | 163 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.5M | 207.5M |
| IPO Year | N/A | 1999 |
| Metric | IPHA | IMMR |
|---|---|---|
| Price | $1.76 | $6.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.75 | ★ $13.50 |
| AVG Volume (30 Days) | 134.2K | ★ 486.2K |
| Earning Date | 03-26-2026 | 04-13-2026 |
| Dividend Yield | N/A | ★ 5.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $35,013,000.00 |
| Revenue This Year | $180.36 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $321.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $5.25 |
| 52 Week High | $2.63 | $8.15 |
| Indicator | IPHA | IMMR |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 58.26 |
| Support Level | $1.72 | $6.33 |
| Resistance Level | $2.32 | $6.88 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 40.00 | 70.36 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.